David Turkaly, an analyst from JMP Securities, reiterated the Buy rating on TELA Bio (TELA – Research Report). The associated price ...

Canaccord Genuity analyst Caitlin Cronin has maintained their bullish stance on TELA stock, giving a Buy rating yesterday. Caitlin Cronin’s rating is based on multiple factors that highlight TELA ...

TELA Bio Inc (NASDAQ:TELA) reported a strong third quarter with a 26% year-over-year revenue increase, reaching $19 million. The company experienced significant growth in its European business ...

For Tela, there aren’t any characteristics of Trump’s masculinity that resonate with him. Trump’s comments about Haitian ...

TELA has been the subject of a number of research reports. Lake Street Capital reduced their target price on shares of TELA Bio from $14.00 to $8.00 and set a “buy” rating for the company in a ...

TELA Bio (TELA) delivered earnings and revenue surprises of -13.51% and 0.75%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

The skies will be mostly cloudy. The high will reach 87° on this humid day. Good air quality (0-50) Primary pollutant O₃ 58 μg/m³ Pressure is the weight of the air in the atmosphere. It is normalized ...

Everard Best met Téla D’Amore on the streets of New York City’s Lower East Side . Years later, the duo would helm a defining ...

Gross profit was $12.9 million in the third quarter of 2024, or 68% of revenue, compared to $10.4 million, or 69% of revenue, in the same period in 2023. The decrease in gross margin was primarily due ...

MALVERN, Pa., Nov. 01, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction ...

Full Year Revenue Guidance: $74.5 million to $76.5 million for 2024, reflecting growth of 28% to 31% over 2023. TELA Bio Inc ...